Riviciclib
Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively[1][2]. Riviciclib shows antitumor activity on cisplatin-resistant cells[3].
Product Specifications
CAS Number
920113-02-6
Product Name Alternative
P276-00 (free base)
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Riviciclib.html
Solubility
10 mM in DMSO
Smiles
O=C1C=C(C2=C(Cl)C=CC=C2)OC3=C([C@H]4[C@H](CO)N(C)CC4)C(O)=CC(O)=C13
Molecular Formula
C21H20ClNO5
Molecular Weight
401.84
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CDK1; CDK2; CDK4; CDK6; CDK9
Citation 01
Int J Mol Sci. 2022 Feb 24;23 (5) :2493.|Elife. 2020 Dec 7;9:e61405.|Pharmaceuticals (Basel) . 2024 Apr 29;17 (5) :569.
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PDHB (PHE1B, Pyruvate Dehydrogenase E1 Component Subunit beta, Mitochondrial, PDHE1-B, DKFZp564K0164) (FITC)
AIMP1 (Aminoacyl tRNA Synthetase Complex-interacting Multifunctional Protein 1, p43, HLD3, EMAP2, SCYE1, EMAPII) (MaxLight 405)
AIMP1 (Aminoacyl tRNA Synthetase Complex-interacting Multifunctional Protein 1, p43, HLD3, EMAP2, SCYE1, EMAPII) (MaxLight 405)
